Tiblio
Sign Up

FULC

Fulcrum Therapeutics Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$285.35M
P/E Ratio
—
EPS
$-1.21
Beta
2.58
52W High
$15.74
52W Low
$2.83
50-Day MA
$3.78
200-Day MA
$6.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)$-56.10M
EBITDA$-85.40M
Operating Margin0.00%
Return on Equity-32.40%
Return on Assets-19.60%
Revenue/Share (TTM)$0.00
Book Value$4.07
Price-to-Book0.94
Price-to-Sales (TTM)2.66
EV/Revenue117.4
EV/EBITDA-3.10
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-100.00%
Shares Outstanding$76.30M
Float$63.49M
% Insiders3.35%
% Institutions103.51%

Historical Volatility

HV 10-Day
11.83%
HV 20-Day
10.65%
HV 30-Day
13.60%
HV 60-Day
28.57%
HV Rank
—

Volatility is currently contracting

Analyst Ratings

Consensus ($3.67 target)
5
Hold
1
Strong Sell

Latest News

Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp9/24/2026Neutral
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)

BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

GlobeNewsWire9/23/2026Neutral
Kaplan Fox Broadens its Investigation of Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp9/22/2026Neutral
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Learn More About the Firm's Investigation

New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp9/18/2026Neutral
Kaplan Fox Shareholder Alert: Fulcrum Therapeutics, Inc. (FULC) is Under Investigation for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp9/16/2026Neutral
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Investors Who Suffered Losses

New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp9/14/2026Neutral
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

GlobeNewsWire9/9/2026Neutral
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (FULC) of an Ongoing Securities Investigation

New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp9/9/2026Neutral
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Shareholders for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp9/4/2026Neutral
Kaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (FULC) of a Securities Law Investigation

New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Newsfile Corp8/31/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FULC and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncMRKMerck & Company IncUNHUnitedHealth Group IncorporatedNVSNovartis AG ADRAZNAstraZeneca PLCTMOThermo Fisher Scientific IncAMGNAmgen IncGILDGilead Sciences IncABTAbbott LaboratoriesNVONovo Nordisk A/S
View all HEALTHCARE stocks →
Data last updated: 9/26/2026